Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + pembrolizumab versus placebo + pembrolizumab as adjuvant therapy after nephrectomy for clear cell renal cell carcinoma
MOH_2022-01-19_010539Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of belzutifan and pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Merck & Co. Started Jan 2022; status: active, not recruiting.
02
Drugs
belzutifanpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on MOH_2022-01-19_010539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-19_010539.